Sign in Subscribe
Pharmaceutical industry

Carrington Laboratories Receives U.S. Patent for Antigen-Sparing Influenza Vaccines

Strategic Insights

— 1 min read

Carrington Laboratories, Inc.'s subsidiary DelSite Biotechnologies, Inc. has developed a technology that uses GelSite polymer to reduce the amount of antigen required for protective immunity by up to 16 times, enabling the expansion of one million standard doses to 16 million doses. This technology is crucial for addressing potential influenza vaccine shortages during seasonal epidemics and possible pandemic outbreaks.

Key Takeaways:

  • DelSite Biotechnologies has developed a technology that uses GelSite polymer to reduce the amount of antigen required for protective immunity by up to 16 times.
  • The technology enables the expansion of one million standard doses to 16 million doses, addressing potential influenza vaccine shortages.
  • Carrington Laboratories' patent, "Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation," adds to the company's strong patent position in drug delivery technologies.
  • DelSite's sustained release and powder delivery technology is the foundation and strength of the company, as stated by CEO Carlton Turner.
  • GelSite polymer is being developed as a controlled-release drug delivery technology for pharmaceutical and vaccine products.
  • DelSite is currently developing new vaccines for seasonal as well as pandemic (avian) influenza, including a proprietary GelVac nasal powder delivery system.
  • The GelVac avian flu vaccine is uniquely suited to meeting the challenges of a pandemic, including stability at room temperature, no refrigeration requirements, and ease of administration.

Statistics:

  • Up to 16 times reduction in antigen required for protective immunity using DelSite's technology.
  • Expansion of one million standard doses to 16 million doses.
  • $6 million NIH/NIAID preclinical development grant for H5N1 avian influenza.
  • No refrigeration required for shipping or prolonged storage of GelVac avian flu vaccine.

Sources:

  • Breast Cancer Discovery News, U.S. Patent Issued to Carrington Labs (CARN) for Compositions Comprising Pectins Having High Molecular Weights and Low Degrees of Methoxylation (2006, World Disease Weekly via NewsRx.com)
  • World Disease Weekly editors from staff and other reports (2006)
  • NewsRx.com (2006)
  • World Disease Weekly (2006)

Read more